Contribute Try STAT+ Today

Amid intense concern that low-income countries lack access to Covid-19 vaccines, Moderna (MRNA) announced plans to build a manufacturing plant in Africa that can produce up to 500 million doses each year for different diseases in a bid to combat the pandemic and other illnesses on a wider scale.

But the move was quickly panned by patient advocates who saw a public relations gambit for thwarting efforts to convince drug makers to share technology, which could be used by other companies to boost vaccine production for global distribution more quickly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment